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Abstract 
Background: Clozapine is widely prescribed and, although effective, can cause weight gain and dysglycemia. The 
dysmetabolic effects of clozapine are thought to be more prevalent in women with this gender on average attaining 
17 % higher plasma clozapine concentrations than men.
Methods: We investigated the relationship between dose, body mass index (BMI), plasma glucose concentration, 
and plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in 100 individuals with a severe 
enduring mental illness.
Results: Mean (10th/90th percentile) plasma clozapine concentrations were higher for women [0.49 (0.27–0.79) 
mg/L] compared with men [0.44 (0.26–0.70) mg/L] (F = 2.2; p = 0.035). There was no significant gender difference 
in the prescribed clozapine dose. BMI was significantly higher in women [mean (95 % CI) = 34.5 (26.0–45.3)] for 
females compared with 32.5 (25.2–41.0) for males. Overall, BMI increased by 0.7 kg/m2 over a mean follow-up period 
of 210 days. A lower proportion, 41 % of women had a fasting blood glucose ≤6.0 mmol/L (<6.0 mmol/L is defined 
by the International Diabetes Federation as normal glucose handling), compared with 88 % of men (χ2 = 18.6, 
p < 0.0001).
Conclusions: We have shown that mean BMI and blood glucose concentrations are higher in women prescribed 
clozapine than in men. Women also tended to attain higher plasma clozapine concentrations than men. The higher 
BMI and blood glucose in women may relate to higher tissue exposure to clozapine, as a consequence of sex differ-
ences in drug metabolism.
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Background
Clozapine is widely prescribed for treatment-resistant 
schizophrenia (TRS) and is also indicated in bipolar I 
disorder. Evidence of superior efficacy compared with 
other first and second generation neuroleptics used for 
the treatment of psychosis is manifest in individual tri-
als and in meta-analyses [1]. However, there is concern 
because the common longer-term side effects of clozap-
ine include weight gain, elevation of blood glucose con-
centrations, dyslipidemia (and ‘metabolic syndrome’), as 
well as somnolence, dizziness, hypersalivation, gastroin-
testinal hypomotility, peripheral oedema, and postural 
hypotension.
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The dysmetabolic effects of clozapine are thought to 
be more prevalent in women [2] and it has been shown 
that gender does have an influence on the observed inter-
patient variability in plasma clozapine concentrations, 
with women on average attaining 17  % higher plasma 
clozapine concentrations than men at constant dose 
irrespective of smoking habit [3]. This is in keeping with 
already identified gender-related differences in pharma-
cokinetics for some drugs, including theophylline and 
several benzodiazepines, known since the 1980s [4].
The initial clozapine dose is 12.5  mg/day, increasing 
gradually to 300–400 mg/day, up to a licensed maximum 
of 900 mg/day.
Therapeutic drug monitoring (TDM) of clozapine and 
N-desmethylclozapine (norclozapine) is useful when 
assessing therapeutic effectiveness and for dose optimisa-
tion [5, 6] and may also be relevant to assessing the meta-
bolic consequences of treatment with clozapine.
In order to gather information as to whether the gender 
differences in clozapine and norclozapine concentrations 
might influence body mass index (BMI), glycaemia and 
lipidemia, we have examined data from a single tertiary 
UK hospital clozapine clinic.
Methods
We carried out a retrospective review of inpatients and 
outpatients (n =  100) with clozapine TDM and consec-
utively assessed results in 2014. All patients had schizo-
phrenia or schizoaffective disorder. All patients were 
treatment resistant, hence treatment with Clozapine. Out 
of the 100 patients, 82 were diagnosed with Schizophre-
nia and 18 with Schizoaffective Disorder.
Data was obtained from the analysis of plasma samples 
submitted for routine TDM in patients seen in Salford 
Community Mental Health Centres or patients seen in 
clozapine clinics on the Prestwich Hospital site (Prest-
wich, Greater Manchester, UK). Ethical approval was 
obtained for the study.
Data recorded with each sample included: prescribed 
clozapine dose (mg/day), duration of clozapine treat-
ment, age, gender, body weight (kg), height (m), smoking 
habit (number of cigarettes/day), and any other informa-
tion that could aid interpretation of the results, for exam-
ple, co-prescribed drugs (and doses).
Plasma clozapine concentrations were related to BMI 
(at time of sampling) and plasma glucose concentrations 
(at the time of sampling). For clozapine TDM, it was 
requested that samples be collected at least 6 h post-dose 
(‘trough’ samples). BMI was calculated as weight (kg)/
height2 (m2).
Plasma glucose and lipids were analyzed using a Roche 
Cobas 8000 autoanalyser, (Roche Diagnostics, Burgess 
Hill, West Sussex, UK), according to the manufacturer’s 
instructions. Analysis was carried out at the biochemistry 
laboratory at Salford Royal Hospital, Greater Manchester, 
UK. Plasma clozapine and norclozapine were measured 
at King’s College Hospital (London, UK) by high-perfor-
mance liquid chromatography with ultraviolet detection 
(240 nm) after extraction into methyl tert-butyl ether at 
pH 10.6. Intra-assay precision was between 3.8 and 6.6 %. 
Corresponding inter-assay precision was between 5.6 and 
15.2 % [7].
Statistical analysis
All analyses were conducted using Stata/MP statistical soft-
ware (version 13.1, College Station, Texas, USA). Categori-
cal variables were compared using the Chi-squared test 
and continuous variables were compared using t tests or 
analysis of variance. Distributions of BMI and clozapine by 
gender were compared using Epanechnikov kernel density 
plots. The ethnicity profile of men and women was similar.
Results
A total of 41 female and 59 male patients were included 
in the study. Males were on average younger than females 
with a mean [95 % confidence interval (CI)] age of 36.9 
(33.9–39.8) years and 39 (35.4–42.7) years, respectively. 
The duration of clozapine treatment was not significantly 
different (p  =  0.6), with a mean (95  % CI) duration of 
4.4 (1.2–10.3) years in males and 5.1 (2.3–7.9) years in 
females, and there was no significant difference in pre-
scribed clozapine dose, with a mean (95 % CI) dose of 433 
(389–477) mg/day and 425 (388–462) mg/day for males 
and females, respectively. Where smoking status was 
recorded, 75.5 % of males and 63.9 % of females smoked.
Overall, BMI increased by 0.7  kg/m2 over a mean 
follow-up period of 210  days from the start of weight 
monitoring.
Twelve patients were taking a second neuroleptic agent 
[aripiprazole (n = 6), amisulpride (n = 4), and haloperi-
dol (n = 2)]. Of the females, five were prescribed an oes-
trogen-containing oral contraceptive pill and three were 
prescribed an oestrogen-containing hormone replace-
ment treatment.
Clozapine and norclozapine TDM
Mean (10th/90th percentile) plasma clozapine concen-
trations were higher for females [0.49 (0.27–0.79) mg/L] 
compared with males [0.44 (0.26–0.70) mg/L] (F =  2.2; 
p  =  0.035, Fig.  1a). There was no gender difference in 
plasma norclozapine concentrations [0.31 (0.26–0.35) 
mg/L and 0.31 (0.27–0.34) mg/L for males and females, 
respectively]. A higher proportion of the samples from 
females had plasma clozapine concentrations of 0.60–
1.00 mg/L (25 % of samples from females compared with 
14  % of samples from males) and >1.00  mg/L (11  % of 
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samples from females compared with 6.6  % of samples 
from males).
Metabolic investigations
BMI was significantly higher in women [mean (95  % 
CI) =  34.5 (26.0–45.3)] for females compared with 32.5 
(25.2–41.0) for males; F  =  3.8, p  =  0.02, Fig.  1b). For 
women, 41 % had a fasting blood glucose ≤6.0 mmol/L 
(<6.0  mmol/L is defined by the International Diabetes 
Federation as normal glucose handling [8]), compared 
with 88  % of men (χ2 =  18.6, p  <  0.0001). High-density 
lipoprotein (HDL)-cholesterol was significantly lower in 
males than in females [mean (95 % CI) = 1.1 (0.97–1.4) 
mmol/L and 1.2 (1.1–1.3) mmol/L for males and females, 
respectively; F = 4.3; p = 0.04].
Discussion
These data provide further evidence that females are 
attaining higher plasma clozapine concentrations in rou-
tine clinical practice than males after allowing for dif-
ferences in prescribed dose and smoking status [9]. The 
effect of gender on plasma clozapine concentration might 
at first sight be considered anomalous since females tend 
to have more adipose tissue than males; hence, lipophilic 
drugs such as clozapine might be expected to show a 
lower plasma concentration at a given dose than males. 
However, this anomaly may be explained by evidence 
that (1) men have higher activities of drug-metabolizing 
cytochromes than women and (2) there are known sex 
differences in pharmacokinetic factors, in particular, renal 
clearance rate is generally slower in females [2]. Another 
potential factor, which might explain the gender differ-
ence in clozapine levels and the clozapine:norclozapine 
ratio, is that women are probably more likely to be fully 
adherent with their medication than men.
In this study, there was no significant gender difference 
associated with plasma norclozapine concentrations, and 
so the clozapine:norclozapine ratio was higher in females. 
This is an important finding, consistent with these known 
sex differences in drug metabolism and clearance, since 
females may be at increased risk of clozapine accumula-
tion than males at a given dose.
We have also shown that BMI and plasma glucose con-
centrations were on average higher in the females than in 
the males in this study. These findings may relate directly 
to greater tissue exposure to clozapine and/or norclozap-
ine. Differences by gender in HDL-cholesterol (lower in 
men) were in keeping with general population patterns.
Whilst our data are based on observational findings 
in a relatively small number of samples, and take no 
account of possible partial- or non-adherence to medica-
tion, the higher clozapine concentrations and the higher 
clozapine:norclozapine ratio may be significant factors 
determining the increased incidence of weight gain and 
dysmetabolic profiles in females prescribed clozapine. 
They may also explain increased incidence of other clo-
zapine-related side effects in females. A potential factor 
that requires further investigation is the effect of oestro-
gen and oral contraceptives in inhibiting drug-metaboliz-
ing enzyme activity in women [10].
Conclusions
Though treatment with clozapine offers significant ben-
efits for many patients with TRS, it is associated with a 
high incidence of substantial weight gain, especially in 
females. We have shown that mean BMI and blood glu-
cose concentrations are higher in females prescribed clo-
zapine than in males, and provided further evidence from 
TDM data that this may relate to higher tissue exposure 
over time to clozapine and/or norclozapine.
It is clear that plasma clozapine concentrations well 
above the suggested (sex-independent) target ranges are 
more frequent in females. Psychiatrists should take into 
account gender differences when prescribing clozapine, 
Fig. 1 Kernel density distribution of age-adjusted a clozapine levels and b BMI by gender
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and should make use of TDM to guard against clozap-
ine accumulation, which may be more likely in females 
prescribed the drug, with the attendant metabolic 
consequences.
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